Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections

Publisher Website
Google Scholar
Abstract
R837 is an immune modulator with no in vitro activity against herpes simplex virus (HSV). We evaluated topical R837 as therapy for genital HSV type 2 infection using the guinea pig model of this disease. Furthermore, we investigated the effect of R837 therapy on acute and latent neural HSV infections. Therapy initiated 12 h after viral inoculation and given twice a day significantly reduced the acute neural infection so that HSV was recovered from only 1 of 64 neural tissue specimens obtained from R837 recipients compared with 43 of 56 specimens obtained from placebo recipients (P < 0.0001). R837 initiated 36 h after HSV inoculation and given once a day also significantly reduced the total mean lesion score of the acute disease from 14.1 .+-. 4.3 to 2.6 .+-. 5.3 (P < 0.0001) and shortened the period of vaginal HSV shedding from 6.9 .+-. 1.7 to 3.2 .+-. 1.4 days (p < 0.001). R837-treated animals also developed fewer HSV recurrences than did controls (2.0 .+-. 1.7 versus 5.1 .+-. 1.7; P < 0.0002). Latent HSV was detected in 23 of 24 dorsal root ganglia explant cultures from placebo recipients but in only 2 of 30 cultures from R837-treated animals, and HSV in these 2 cultures was detectable only with the addition of a demethylating agent. Topical R837 exhibited in vivo anti-HSV activity, reducing both acute and latent neural infections as well as acute and recurrent genital disease.

This publication has 25 references indexed in Scilit: